Antibodies and protein misfolding: From structural research tools to therapeutic strategies

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1844, Issue 11, 2014, Pages 1907-1919

  De Genst, Erwin ^a   Messer, Anne ^b,c   Dobson, Christopher M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Regenerative Research Foundation   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Amyloid; Antibody; Immunotherapy; Neurodegenerative disease; Protein misfolding

Indexed keywords

AMYLOID PROTEIN; ANTIBODY; MONOCLONAL ANTIBODY; OLIGOMER;

BIOPHYSICS; CYTOTOXICITY; HUMAN; HUNTINGTON CHOREA; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; METHODOLOGY; MICROSCOPY; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; OLIGOMERIZATION; PARKINSON DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN AGGREGATION; PROTEIN ENGINEERING; PROTEIN FOLDING; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; SPECTROSCOPY;

EID: 84907938241     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2014.08.016     Document Type: Review

References (220)

1. V.K. Mulligan, and A. Chakrabartty Protein misfolding in the late-onset neurodegenerative diseases: common themes and the unique case of amyotrophic lateral sclerosis Proteins 81 2013 1285 1303
2. N.B. Bolshette, K.K. Thakur, A.P. Bidkar, C. Trandafir, P. Kumar, and R. Gogoi Protein folding and misfolding in the neurodegenerative disorders: a review Rev. Neurol. (Paris) 170 2014 151 161
3. P. Arosio, M. Vendruscolo, C.M. Dobson, and T.P. Knowles Chemical kinetics for drug discovery to combat protein aggregation diseases Trends Pharmacol. Sci. 35 2014 127 135
4. F. Chiti, and C.M. Dobson Protein misfolding, functional amyloid, and human disease Annu. Rev. Biochem. 75 2006 333 366
5. A. Messer, and S.N. Joshi Intrabodies as neuroprotective therapeutics Neurotherapeutics 10 2013 447 458
6. L.M. Blancas-Mejia, and M. Ramirez-Alvarado Systemic amyloidoses Annu. Rev. Biochem. 82 2013 745 774
7. R.A. Kyle Amyloidosis: a convoluted story Br. J. Haematol. 114 2001 529 538
8. M. Stefani Generic cell dysfunction in neurodegenerative disorders: role of surfaces in early protein misfolding, aggregation, and aggregate cytotoxicity Neuroscientist 13 2007 519 531
9. T. Eichner, and S.E. Radford A diversity of assembly mechanisms of a generic amyloid fold Mol. Cell 43 2011 8 18
10. M. Vendruscolo, T.P. Knowles, and C.M. Dobson Protein solubility and protein homeostasis: a generic view of protein misfolding disorders Cold Spring Harb. Perspect. Biol. 3 2011
11. T.P. Knowles, M. Vendruscolo, and C.M. Dobson The amyloid state and its association with protein misfolding diseases Nat. Rev. Mol. Cell Biol. 15 2014 384 396
12. F. Chiti, and C.M. Dobson Amyloid formation by globular proteins under native conditions Nat. Chem. Biol. 5 2009 15 22
13. C.M. Dobson Protein misfolding, evolution and disease Trends Biochem. Sci. 24 1999 329 332
14. C.M. Dobson Protein folding and misfolding Nature 426 2003 884 890
15. L.M. Luheshi, D.C. Crowther, and C.M. Dobson Protein misfolding and disease: from the test tube to the organism Curr. Opin. Chem. Biol. 12 2008 25 31
16. L.M. Luheshi, and C.M. Dobson Bridging the gap: from protein misfolding to protein misfolding diseases FEBS Lett. 583 2009 2581 2586
17. M. Stefani, and C.M. Dobson Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution J. Mol. Med. 81 2003 678 699
18. M. Vendruscolo, J. Zurdo, C.E. MacPhee, and C.M. Dobson Protein folding and misfolding: a paradigm of self-assembly and regulation in complex biological systems Philos. Trans. A Math. Phys. Eng. Sci. 361 2003 1205 1222
19. C.F. Wright, S.A. Teichmann, J. Clarke, and C.M. Dobson The importance of sequence diversity in the aggregation and evolution of proteins Nature 438 2005 878 881
20. H. Ecroyd, and J.A. Carver Unraveling the mysteries of protein folding and misfolding IUBMB Life 60 2008 769 774
21. T.P. Knowles, C.A. Waudby, G.L. Devlin, S.I. Cohen, A. Aguzzi, M. Vendruscolo, E.M. Terentjev, M.E. Welland, and C.M. Dobson An analytical solution to the kinetics of breakable filament assembly Science 326 2009 1533 1537
22. S.I. Cohen, M. Vendruscolo, C.M. Dobson, and T.P. Knowles From macroscopic measurements to microscopic mechanisms of protein aggregation J. Mol. Biol. 421 2012 160 171
23. S.I. Cohen, S. Linse, L.M. Luheshi, E. Hellstrand, D.A. White, L. Rajah, D.E. Otzen, M. Vendruscolo, C.M. Dobson, and T.P. Knowles Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism Proc. Natl. Acad. Sci. U. S. A. 110 2013 9758 9763
24. J.D. Sipe, and A.S. Cohen Review: history of the amyloid fibril J. Struct. Biol. 130 2000 88 98
25. C.M. Dobson Protein folding and its links with human disease Biochem. Soc. Symp. 2001 1 26
26. M. Fandrich, M.A. Fletcher, and C.M. Dobson Amyloid fibrils from muscle myoglobin Nature 410 2001 165 166
27. M.B. Pepys, P.N. Hawkins, D.R. Booth, D.M. Vigushin, G.A. Tennent, A.K. Soutar, N. Totty, O. Nguyen, C.C. Blake, and C.J. Terry Human lysozyme gene mutations cause hereditary systemic amyloidosis Nature 362 1993 553 557
28. D.A. Lomas, D.L. Evans, J.T. Finch, and R.W. Carrell The mechanism of Z alpha 1-antitrypsin accumulation in the liver Nature 357 1992 605 607
29. M. Bucciantini, G. Calloni, F. Chiti, L. Formigli, D. Nosi, C.M. Dobson, and M. Stefani Prefibrillar amyloid protein aggregates share common features of cytotoxicity J. Biol. Chem. 279 2004 31374 31382
30. A.K. Buell, C. Galvagnion, R. Gaspar, E. Sparr, M. Vendruscolo, T.P. Knowles, S. Linse, and C.M. Dobson Solution conditions determine the relative importance of nucleation and growth processes in alpha-synuclein aggregation Proc. Natl. Acad. Sci. U. S. A. 111 2014 7671 7676
31. M. Cheon, I. Chang, S. Mohanty, L.M. Luheshi, C.M. Dobson, M. Vendruscolo, and G. Favrin Structural reorganisation and potential toxicity of oligomeric species formed during the assembly of amyloid fibrils PLoS Comput. Biol. 3 2007 1727 1738
32. N. Lorenzen, L. Lemminger, J.N. Pedersen, S.B. Nielsen, and D.E. Otzen The N-terminus of alpha-synuclein is essential for both monomeric and oligomeric interactions with membranes FEBS Lett. 588 2014 497 502
33. C. Cecchi, and M. Stefani The amyloid-cell membrane system. The interplay between the biophysical features of oligomers/fibrils and cell membrane defines amyloid toxicity Biophys. Chem. 182 2013 30 43
34. M. Stefani Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer's disease and other diseases with amyloid deposits Prog. Neurobiol. 99 2012 226 245
35. B.L. Kagan, and J. Thundimadathil Amyloid peptide pores and the beta sheet conformation Adv. Exp. Med. Biol. 677 2010 150 167
36. D.A. Gimbel, H.B. Nygaard, E.E. Coffey, E.C. Gunther, J. Lauren, Z.A. Gimbel, and S.M. Strittmatter Memory impairment in transgenic Alzheimer mice requires cellular prion protein J. Neurosci. 30 2010 6367 6374
37. J. Lauren, D.A. Gimbel, H.B. Nygaard, J.W. Gilbert, and S.M. Strittmatter Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers Nature 457 2009 1128 1132
38. G.M. Shankar, B.L. Bloodgood, M. Townsend, D.M. Walsh, D.J. Selkoe, and B.L. Sabatini Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway J. Neurosci. 27 2007 2866 2875
39. M. Cisse, B. Halabisky, J. Harris, N. Devidze, D.B. Dubal, B. Sun, A. Orr, G. Lotz, D.H. Kim, P. Hamto, K. Ho, G.Q. Yu, and L. Mucke Reversing EphB2 depletion rescues cognitive functions in Alzheimer model Nature 469 2011 47 52
40. R. Kayed, and C.A. Lasagna-Reeves Molecular mechanisms of amyloid oligomers toxicity J. Alzheimers Dis. 33 Suppl. 1 2013 S67 S78
41. A.J. Nicoll, S. Panico, D.B. Freir, D. Wright, C. Terry, E. Risse, C.E. Herron, T. O'Malley, J.D. Wadsworth, M.A. Farrow, D.M. Walsh, H.R. Saibil, and J. Collinge Amyloid-beta nanotubes are associated with prion protein-dependent synaptotoxicity Nat. Commun. 4 2013 2416
42. S.D. Yan, X. Chen, J. Fu, M. Chen, H. Zhu, A. Roher, T. Slattery, L. Zhao, M. Nagashima, J. Morser, A. Migheli, P. Nawroth, D. Stern, and A.M. Schmidt RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease Nature 382 1996 685 691
43. H.Y. Wang, D.H. Lee, C.B. Davis, and R.P. Shank Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors J. Neurochem. 75 2000 1155 1161
44. H.Y. Wang, D.H. Lee, M.R. D'Andrea, P.A. Peterson, R.P. Shank, and A.B. Reitz Beta-amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology J. Biol. Chem. 275 2000 5626 5632
45. P.B. Verghese, J.M. Castellano, K. Garai, Y. Wang, H. Jiang, A. Shah, G. Bu, C. Frieden, and D.M. Holtzman ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions Proc. Natl. Acad. Sci. U. S. A. 110 2013 E1807 E1816
46. M.J. LaDu, W.B. Stine Jr., M. Narita, G.S. Getz, C.A. Reardon, and G. Bu Self-assembly of HEK cell-secreted ApoE particles resembles ApoE enrichment of lipoproteins as a ligand for the LDL receptor-related protein Biochemistry 45 2006 381 390
47. J. Leitman, B. Barak, R. Benyair, M. Shenkman, U. Ashery, F.U. Hartl, and G.Z. Lederkremer ER stress-induced eIF2-alpha phosphorylation underlies sensitivity of striatal neurons to pathogenic huntingtin PLoS ONE 9 2014 e90803
48. J. Leitman, F. Ulrich Hartl, and G.Z. Lederkremer Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress Nat. Commun. 4 2013 2753
49. F. Haun, T. Nakamura, A.D. Shiu, D.H. Cho, T. Tsunemi, E.A. Holland, A.R. La Spada, and S.A. Lipton S-nitrosylation of dynamin-related protein 1 mediates mutant huntingtin-induced mitochondrial fragmentation and neuronal injury in Huntington's disease Antioxid. Redox Signal. 19 2013 1173 1184
50. H.B. Fernandes, K.G. Baimbridge, J. Church, M.R. Hayden, and L.A. Raymond Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease J. Neurosci. 27 2007 13614 13623
51. D.T. Chang, G.L. Rintoul, S. Pandipati, and I.J. Reynolds Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons Neurobiol. Dis. 22 2006 388 400
52. E. Kvam, B.L. Nannenga, M.S. Wang, Z. Jia, M.R. Sierks, and A. Messer Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity PLoS ONE 4 2009 e5727
53. B.D. Paul, J.I. Sbodio, R. Xu, M.S. Vandiver, J.Y. Cha, A.M. Snowman, and S.H. Snyder Cystathionine gamma-lyase deficiency mediates neurodegeneration in Huntington's disease Nature 509 2014 96 100
54. H. Tsoi, and H.Y. Chan Expression of expanded CAG transcripts triggers nucleolar stress in Huntington's disease Cerebellum 12 2013 310 312
55. A. Kazantsev, E. Preisinger, A. Dranovsky, D. Goldgaber, and D. Housman Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells Proc. Natl. Acad. Sci. U. S. A. 96 1999 11404 11409
56. C.C. Huang, P.W. Faber, F. Persichetti, V. Mittal, J.P. Vonsattel, M.E. MacDonald, and J.F. Gusella Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins Somat. Cell Mol. Genet. 24 1998 217 233
57. J.M. Boutell, P. Thomas, J.W. Neal, V.J. Weston, J. Duce, P.S. Harper, and A.L. Jones Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin Hum. Mol. Genet. 8 1999 1647 1655
58. S.H. Park, Y. Kukushkin, R. Gupta, T. Chen, A. Konagai, M.S. Hipp, M. Hayer-Hartl, and F.U. Hartl PolyQ proteins interfere with nuclear degradation of cytosolic proteins by sequestering the Sis1p chaperone Cell 154 2013 134 145
59. N. Cremades, S.I. Cohen, E. Deas, A.Y. Abramov, A.Y. Chen, A. Orte, M. Sandal, R.W. Clarke, P. Dunne, F.A. Aprile, C.W. Bertoncini, N.W. Wood, T.P. Knowles, C.M. Dobson, and D. Klenerman Direct observation of the interconversion of normal and toxic forms of alpha-synuclein Cell 149 2012 1048 1059
60. M.J. Volles, and P.T. Lansbury Jr. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism Biochemistry 41 2002 4595 4602
61. M.J. Volles, S.J. Lee, J.C. Rochet, M.D. Shtilerman, T.T. Ding, J.C. Kessler, and P.T. Lansbury Jr. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease Biochemistry 40 2001 7812 7819
62. Q. Liu, S. Emadi, J.X. Shen, M.R. Sierks, and J. Wu Human alpha4beta2 nicotinic acetylcholine receptor as a novel target of oligomeric alpha-synuclein PLoS ONE 8 2013 e55886
63. C. Kim, D.H. Ho, J.E. Suk, S. You, S. Michael, J. Kang, S. Joong Lee, E. Masliah, D. Hwang, H.J. Lee, and S.J. Lee Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia Nat. Commun. 4 2013 1562
64. G. Kohler, and C. Milstein Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 1975 495 497
65. Kitasato Behring On the development of immunity to diphtheria and tetanus in animals Dtsch. Med. Wochenschr. 90 1965 2183
66. G. Winter, and C. Milstein Man-made antibodies Nature 349 1991 293 299
67. J. McCafferty, A.D. Griffiths, G. Winter, and D.J. Chiswell Phage antibodies: filamentous phage displaying antibody variable domains Nature 348 1990 552 554
68. B. Dreier, and A. Pluckthun Ribosome display: a technology for selecting and evolving proteins from large libraries Methods Mol. Biol. 687 2011 283 306
69. J. Hanes, and A. Pluckthun In vitro selection and evolution of functional proteins by using ribosome display Proc. Natl. Acad. Sci. U. S. A. 94 1997 4937 4942
70. M.J. Feldhaus, and R.W. Siegel Yeast display of antibody fragments: a discovery and characterization platform J. Immunol. Methods 290 2004 69 80
71. J.S. Swers, B.A. Kellogg, and K.D. Wittrup Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display Nucleic Acids Res. 32 2004 e36
72. H.R. Hoogenboom Selecting and screening recombinant antibody libraries Nat. Biotechnol. 23 2005 1105 1116
73. T.W. Miller, and A. Messer Intrabody applications in neurological disorders: progress and future prospects Mol. Ther. 12 2005 394 401
74. J.S. Huston, and A.J. George Engineered antibodies take center stage Hum. Antibodies 10 2001 127 142
75. P.D. Kaiser, J. Maier, B. Traenkle, F. Emele, and U. Rothbauer Recent progress in generating intracellular functional antibody fragments to target and trace cellular components in living cells Biochim. Biophys. Acta 1844 2014 1933 1942
76. E.S. Ward, D. Gussow, A.D. Griffiths, P.T. Jones, and G. Winter Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli Nature 341 1989 544 546
77. J. Davies, and L. Riechmann Antibody VH domains as small recognition units Biotechnology (N Y) 13 1995 475 479
78. K.L. Constantine, M.S. Friedrichs, W.J. Metzler, M. Wittekind, P. Hensley, and L. Mueller Solution structure of an isolated antibody VL domain J. Mol. Biol. 236 1994 310 327
79. L.J. Holt, C. Herring, L.S. Jespers, B.P. Woolven, and I.M. Tomlinson Domain antibodies: proteins for therapy Trends Biotechnol. 21 2003 484 490
80. J.S. Huston, D. Levinson, M. Mudgett-Hunter, M.S. Tai, J. Novotny, M.N. Margolies, R.J. Ridge, R.E. Bruccoleri, E. Haber, and R. Crea Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli Proc. Natl. Acad. Sci. U. S. A. 85 1988 5879 5883
81. C. Hamers-Casterman, T. Atarhouch, S. Muyldermans, G. Robinson, C. Hamers, E.B. Songa, N. Bendahman, and R. Hamers Naturally occurring antibodies devoid of light chains Nature 363 1993 446 448
82. S. Muyldermans, T.N. Baral, V.C. Retamozzo, P. De Baetselier, E. De Genst, J. Kinne, H. Leonhardt, S. Magez, V.K. Nguyen, H. Revets, U. Rothbauer, B. Stijlemans, S. Tillib, U. Wernery, L. Wyns, G. Hassanzadeh-Ghassabeh, and D. Saerens Camelid immunoglobulins and nanobody technology Vet. Immunol. Immunopathol. 128 2009 178 183
83. S. Muyldermans Nanobodies: natural single-domain antibodies Annu. Rev. Biochem. 82 2013 775 797
84. E. De Genst, D. Saerens, S. Muyldermans, and K. Conrath Antibody repertoire development in camelids Dev. Comp. Immunol. 30 2006 187 198
85. S. Muyldermans Single domain camel antibodies: current status J. Biotechnol. 74 2001 277 302
86. S.C. Williams Small nanobody drugs win big backing from pharma Nat. Med. 19 2013 1355 1356
87. P.H. Chan, E. Pardon, L. Menzer, E. De Genst, J.R. Kumita, J. Christodoulou, D. Saerens, A. Brans, F. Bouillenne, D.B. Archer, C.V. Robinson, S. Muyldermans, A. Matagne, C. Redfield, L. Wyns, C.M. Dobson, and M. Dumoulin Engineering a camelid antibody fragment that binds to the active site of human lysozyme and inhibits its conversion into amyloid fibrils Biochemistry 47 2008 11041 11054
88. M. Dumoulin, D. Canet, A.M. Last, E. Pardon, D.B. Archer, S. Muyldermans, L. Wyns, A. Matagne, C.V. Robinson, C. Redfield, and C.M. Dobson Reduced global cooperativity is a common feature underlying the amyloidogenicity of pathogenic lysozyme mutations J. Mol. Biol. 346 2005 773 788
89. M. Dumoulin, A.M. Last, A. Desmyter, K. Decanniere, D. Canet, G. Larsson, A. Spencer, D.B. Archer, J. Sasse, S. Muyldermans, L. Wyns, C. Redfield, A. Matagne, C.V. Robinson, and C.M. Dobson A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme Nature 424 2003 783 788
90. E.J. De Genst, T. Guilliams, J. Wellens, E.M. O'Day, C.A. Waudby, S. Meehan, M. Dumoulin, S.T. Hsu, N. Cremades, K.H. Verschueren, E. Pardon, L. Wyns, J. Steyaert, J. Christodoulou, and C.M. Dobson Structure and properties of a complex of alpha-synuclein and a single-domain camelid antibody J. Mol. Biol. 402 2010 326 343
91. P. Lafaye, I. Achour, P. England, C. Duyckaerts, and F. Rougeon Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation Mol. Immunol. 46 2009 695 704
92. H. Taguchi, S. Planque, G. Sapparapu, S. Boivin, M. Hara, Y. Nishiyama, and S. Paul Exceptional amyloid beta peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds J. Biol. Chem. 283 2008 36724 36733
93. J.M. Perchiacca, A.R. Ladiwala, M. Bhattacharya, and P.M. Tessier Structure-based design of conformation- and sequence-specific antibodies against amyloid beta Proc. Natl. Acad. Sci. U. S. A. 109 2012 84 89
94. A.R. Ladiwala, M. Bhattacharya, J.M. Perchiacca, P. Cao, D.P. Raleigh, A. Abedini, A.M. Schmidt, J. Varkey, R. Langen, and P.M. Tessier Rational design of potent domain antibody inhibitors of amyloid fibril assembly Proc. Natl. Acad. Sci. U. S. A. 109 2012 19965 19970
95. C.G. Glabe Conformation-dependent antibodies target diseases of protein misfolding Trends Biochem. Sci. 29 2004 542 547
96. S. Kasturirangan, T. Reasoner, P. Schulz, S. Boddapati, S. Emadi, J. Valla, and M.R. Sierks Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples Biotechnol. Prog. 29 2013 463 471
97. W.D. Marcus, H. Wang, S.M. Lindsay, and M.R. Sierks Characterization of an antibody scFv that recognizes fibrillar insulin and beta-amyloid using atomic force microscopy Nanomedicine 4 2008 1 7
98. G. Habicht, C. Haupt, R.P. Friedrich, P. Hortschansky, C. Sachse, J. Meinhardt, K. Wieligmann, G.P. Gellermann, M. Brodhun, J. Gotz, K.J. Halbhuber, C. Rocken, U. Horn, and M. Fandrich Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils Proc. Natl. Acad. Sci. U. S. A. 104 2007 19232 19237
99. S. Emadi, R. Liu, B. Yuan, P. Schulz, C. McAllister, Y. Lyubchenko, A. Messer, and M.R. Sierks Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments Biochemistry 43 2004 2871 2878
100. E. De Genst, P.H. Chan, E. Pardon, S.T. Hsu, J.R. Kumita, J. Christodoulou, L. Menzer, D.Y. Chirgadze, C.V. Robinson, S. Muyldermans, A. Matagne, L. Wyns, C.M. Dobson, and M. Dumoulin A nanobody binding to non-amyloidogenic regions of the protein human lysozyme enhances partial unfolding but inhibits amyloid fibril formation J. Phys. Chem. B 117 2013 13245 13258
101. T. Guilliams, F. El-Turk, A.K. Buell, E.M. O'Day, F.A. Aprile, E.K. Esbjorner, M. Vendruscolo, N. Cremades, E. Pardon, L. Wyns, M.E. Welland, J. Steyaert, J. Christodoulou, C.M. Dobson, and E. De Genst Nanobodies raised against monomeric alpha-synuclein distinguish between fibrils at different maturation stages J. Mol. Biol. 425 2013 2397 2411
102. S. Emadi, S. Kasturirangan, M.S. Wang, P. Schulz, and M.R. Sierks Detecting morphologically distinct oligomeric forms of alpha-synuclein J. Biol. Chem. 284 2009 11048 11058
103. C. Zhou, S. Emadi, M.R. Sierks, and A. Messer A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein Mol. Ther. 10 2004 1023 1031
104. S. Emadi, H. Barkhordarian, M.S. Wang, P. Schulz, and M.R. Sierks Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity J. Mol. Biol. 368 2007 1132 1144
105. S.M. Lynch, C. Zhou, and A. Messer An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity J. Mol. Biol. 377 2008 136 147
106. S.N. Joshi, D.C. Butler, and A. Messer Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies MAbs 4 2012 686 693
107. R. Liu, B. Yuan, S. Emadi, A. Zameer, P. Schulz, C. McAllister, Y. Lyubchenko, G. Goud, and M.R. Sierks Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity Biochemistry 43 2004 6959 6967
108. A. Zameer, P. Schulz, M.S. Wang, and M.R. Sierks Single chain Fv antibodies against the 25-35 Abeta fragment inhibit aggregation and toxicity of Abeta42 Biochemistry 45 2006 11532 11539
109. A. Zameer, S. Kasturirangan, S. Emadi, S.V. Nimmagadda, and M.R. Sierks Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells J. Mol. Biol. 384 2008 917 928
110. S. Kasturirangan, L. Li, S. Emadi, S. Boddapati, P. Schulz, and M.R. Sierks Nanobody specific for oligomeric beta-amyloid stabilizes nontoxic form Neurobiol. Aging 33 2012 1320 1328
111. R. Kayed, E. Head, J.L. Thompson, T.M. McIntire, S.C. Milton, C.W. Cotman, and C.G. Glabe Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis Science 300 2003 486 489
112. R. Kayed, E. Head, F. Sarsoza, T. Saing, C.W. Cotman, M. Necula, L. Margol, J. Wu, L. Breydo, J.L. Thompson, S. Rasool, T. Gurlo, P. Butler, and C.G. Glabe Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers Mol. Neurodegener. 2 2007 18
113. A.L. Southwell, A. Khoshnan, D.E. Dunn, C.W. Bugg, D.C. Lo, and P.H. Patterson Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity J. Neurosci. 28 2008 9013 9020
114. J.M. Lecerf, T.L. Shirley, Q. Zhu, A. Kazantsev, P. Amersdorfer, D.E. Housman, A. Messer, and J.S. Huston Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease Proc. Natl. Acad. Sci. U. S. A. 98 2001 4764 4769
115. D.W. Colby, P. Garg, T. Holden, G. Chao, J.M. Webster, A. Messer, V.M. Ingram, and K.D. Wittrup Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display J. Mol. Biol. 342 2004 901 912
116. A. Schiefner, L. Chatwell, J. Korner, I. Neumaier, D.W. Colby, R. Volkmer, K.D. Wittrup, and A. Skerra A disulfide-free single-domain V(L) intrabody with blocking activity towards huntingtin reveals a novel mode of epitope recognition J. Mol. Biol. 414 2011 337 355
117. J. Ko, S. Ou, and P.H. Patterson New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins Brain Res. Bull. 56 2001 319 329
118. A. Khoshnan, J. Ko, and P.H. Patterson Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity Proc. Natl. Acad. Sci. U. S. A. 99 2002 1002 1007
119. C.E. Wang, H. Zhou, J.R. McGuire, V. Cerullo, B. Lee, S.H. Li, and X.J. Li Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin J. Cell Biol. 181 2008 803 816
120. C.A. Gutekunst, S.H. Li, H. Yi, J.S. Mulroy, S. Kuemmerle, R. Jones, D. Rye, R.J. Ferrante, S.M. Hersch, and X.J. Li Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology J. Neurosci. 19 1999 2522 2534
121. R.N. Abskharon, G. Giachin, A. Wohlkonig, S.H. Soror, E. Pardon, G. Legname, and J. Steyaert Probing the N-terminal beta-sheet conversion in the crystal structure of the human prion protein bound to a nanobody J. Am. Chem. Soc. 136 2014 937 944
122. M. Polymenidou, R. Moos, M. Scott, C. Sigurdson, Y.Z. Shi, B. Yajima, I. Hafner-Bratkovic, R. Jerala, S. Hornemann, K. Wuthrich, A. Bellon, M. Vey, G. Garen, M.N. James, N. Kav, and A. Aguzzi The POM monoclonals: a comprehensive set of antibodies to non-overlapping prion protein epitopes PLoS ONE 3 2008 e3872
123. K. Domanska, S. Vanderhaegen, V. Srinivasan, E. Pardon, F. Dupeux, J.A. Marquez, S. Giorgetti, M. Stoppini, L. Wyns, V. Bellotti, and J. Steyaert Atomic structure of a nanobody-trapped domain-swapped dimer of an amyloidogenic beta2-microglobulin variant Proc. Natl. Acad. Sci. U. S. A. 108 2011 1314 1319
124. M. Dumoulin, and C.M. Dobson Probing the origins, diagnosis and treatment of amyloid diseases using antibodies Biochimie 86 2004 589 600
125. E. De Genst, and C.M. Dobson Nanobodies as structural probes of protein misfolding and fibril formation Methods Mol. Biol. 911 2012 533 558
126. D.R. Booth, M. Sunde, V. Bellotti, C.V. Robinson, W.L. Hutchinson, P.E. Fraser, P.N. Hawkins, C.M. Dobson, S.E. Radford, C.C. Blake, and M.B. Pepys Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis Nature 385 1997 787 793
127. M. Lasse, J.A. Gerrard, and F.G. Pearce Aggregation and fibrillogenesis of proteins not associated with disease: a few case studies Subcell. Biochem. 65 2012 253 270
128. M. Dumoulin, J.R. Kumita, and C.M. Dobson Normal and aberrant biological self-assembly: insights from studies of human lysozyme and its amyloidogenic variants Acc. Chem. Res. 39 2006 603 610
129. J. Floege, and G. Ehlerding Beta-2-microglobulin-associated amyloidosis Nephron 72 1996 9 26
130. T.R. Jahn, M.J. Parker, S.W. Homans, and S.E. Radford Amyloid formation under physiological conditions proceeds via a native-like folding intermediate Nat. Struct. Mol. Biol. 13 2006 195 201
131. S.E. Radford, W.S. Gosal, and G.W. Platt Towards an understanding of the structural molecular mechanism of beta(2)-microglobulin amyloid formation in vitro Biochim. Biophys. Acta 1753 2005 51 63
132. D. Ami, S. Ricagno, M. Bolognesi, V. Bellotti, S.M. Doglia, and A. Natalello Structure, stability, and aggregation of beta-2 microglobulin mutants: insights from a Fourier transform infrared study in solution and in the crystalline state Biophys. J. 102 2012 1676 1684
133. M. Colombo, M. de Rosa, V. Bellotti, S. Ricagno, and M. Bolognesi A recurrent D-strand association interface is observed in beta-2 microglobulin oligomers FEBS J. 279 2012 1131 1143
134. S. Azinas, M. Colombo, A. Barbiroli, C. Santambrogio, S. Giorgetti, S. Raimondi, F. Bonomi, R. Grandori, V. Bellotti, S. Ricagno, and M. Bolognesi D-strand perturbation and amyloid propensity in beta-2 microglobulin FEBS J. 278 2011 2349 2358
135. M. Colombo, S. Ricagno, A. Barbiroli, C. Santambrogio, S. Giorgetti, S. Raimondi, F. Bonomi, R. Grandori, V. Bellotti, and M. Bolognesi The effects of an ideal beta-turn on beta-2 microglobulin fold stability J. Biochem. 150 2011 39 47
136. F. Fogolari, A. Corazza, N. Varini, M. Rotter, D. Gumral, L. Codutti, E. Rennella, P. Viglino, V. Bellotti, and G. Esposito Molecular dynamics simulation of beta(2)-microglobulin in denaturing and stabilizing conditions Proteins 79 2011 986 1001
137. V.A. Streltsov, J.N. Varghese, C.L. Masters, and S.D. Nuttall Crystal structure of the amyloid-beta p3 fragment provides a model for oligomer formation in Alzheimer's disease J. Neurosci. 31 2011 1419 1426
138. M.R. Jensen, R.W. Ruigrok, and M. Blackledge Describing intrinsically disordered proteins at atomic resolution by NMR Curr. Opin. Struct. Biol. 23 2013 426 435
139. C.G. Glabe Structural classification of toxic amyloid oligomers J. Biol. Chem. 283 2008 29639 29643
140. C.A. Borrebaeck Antibodies in diagnostics - from immunoassays to protein chips Immunol. Today 21 2000 379 382
141. P.J. Hudson, and C. Souriau Engineered antibodies Nat. Med. 9 2003 129 134
142. R.P. Valle, and M. Jendoubi Antibody-based technologies for target discovery Curr. Opin. Drug Discov. Dev. 6 2003 197 203
143. S.G. Rasmussen, H.J. Choi, J.J. Fung, E. Pardon, P. Casarosa, P.S. Chae, B.T. Devree, D.M. Rosenbaum, F.S. Thian, T.S. Kobilka, A. Schnapp, I. Konetzki, R.K. Sunahara, S.H. Gellman, A. Pautsch, J. Steyaert, W.I. Weis, and B.K. Kobilka Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor Nature 469 2011 175 180
144. J. Steyaert, and B.K. Kobilka Nanobody stabilization of G protein-coupled receptor conformational states Curr. Opin. Struct. Biol. 21 2011 567 572
145. C. Low, Y.H. Yau, E. Pardon, C. Jegerschold, L. Wahlin, E.M. Quistgaard, P. Moberg, S. Geifman-Shochat, J. Steyaert, and P. Nordlund Nanobody mediated crystallization of an archeal mechanosensitive channel PLoS ONE 8 2013 e77984
146. R. Kayed, and C.G. Glabe Conformation-dependent anti-amyloid oligomer antibodies Methods Enzymol. 413 2006 326 344
147. C.G. Glabe Common mechanisms of amyloid oligomer pathogenesis in degenerative disease Neurobiol. Aging 27 2006 570 575
148. C.G. Glabe, and R. Kayed Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis Neurology 66 2006 S74 S78
149. L.S. Shlyakhtenko, B. Yuan, S. Emadi, Y.L. Lyubchenko, and M.R. Sierks Single-molecule selection and recovery of structure-specific antibodies using atomic force microscopy Nanomedicine 3 2007 192 197
150. Y.E. Kim, M.S. Hipp, A. Bracher, M. Hayer-Hartl, and F.U. Hartl Molecular chaperone functions in protein folding and proteostasis Annu. Rev. Biochem. 82 2013 323 355
151. J.M. Barral, S.A. Broadley, G. Schaffar, and F.U. Hartl Roles of molecular chaperones in protein misfolding diseases Semin. Cell Dev. Biol. 15 2004 17 29
152. S.J. Lee, H.S. Lim, E. Masliah, and H.J. Lee Protein aggregate spreading in neurodegenerative diseases: problems and perspectives Neurosci. Res. 70 2011 339 348
153. S.J. Lee, P. Desplats, C. Sigurdson, I. Tsigelny, and E. Masliah Cell-to-cell transmission of non-prion protein aggregates Nat. Rev. Neurol. 6 2010 702 706
154. J. Labbadia, and R.I. Morimoto Huntington's disease: underlying molecular mechanisms and emerging concepts Trends Biochem. Sci. 38 2013 378 385
155. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 1993 971 983
156. S.E. Andrew, Y.P. Goldberg, B. Kremer, H. Telenius, J. Theilmann, S. Adam, E. Starr, F. Squitieri, B. Lin, and M.A. Kalchman The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease Nat. Genet. 4 1993 398 403
157. M. Duyao, C. Ambrose, R. Myers, A. Novelletto, F. Persichetti, M. Frontali, S. Folstein, C. Ross, M. Franz, and M. Abbott Trinucleotide repeat length instability and age of onset in Huntington's disease Nat. Genet. 4 1993 387 392
158. E. Sapp, J. Penney, A. Young, N. Aronin, J.P. Vonsattel, and M. DiFiglia Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease J. Neuropathol. Exp. Neurol. 58 1999 165 173
159. M. DiFiglia, E. Sapp, K.O. Chase, S.W. Davies, G.P. Bates, J.P. Vonsattel, and N. Aronin Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain Science 277 1997 1990 1993
160. T.W. Miller, C. Zhou, S. Gines, M.E. MacDonald, N.D. Mazarakis, G.P. Bates, J.S. Huston, and A. Messer A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease Neurobiol. Dis. 19 2005 47 56
161. E. Kvam, M.R. Sierks, C.B. Shoemaker, and A. Messer Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm Protein Eng. Des. Sel. 23 2010 489 498
162. A.L. Southwell, C.W. Bugg, L.S. Kaltenbach, D. Dunn, S. Butland, A. Weiss, P. Paganetti, D.C. Lo, and P.H. Patterson Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1 PLoS ONE 6 2011 e16676
163. D.C. Butler, J.A. McLear, and A. Messer Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins Prog. Neurobiol. 97 2012 190 204
164. A. Nagarajan, S. Jawahery, and S. Matysiak The effects of flanking sequences in the interaction of polyglutamine peptides with a membrane bilayer J. Phys. Chem. B 118 2014 6368 6379
165. M. Michalek, E.S. Salnikov, S. Werten, and B. Bechinger Membrane interactions of the amphipathic amino terminus of huntingtin Biochemistry 52 2013 847 858
166. R.S. Atwal, J. Xia, D. Pinchev, J. Taylor, R.M. Epand, and R. Truant Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity Hum. Mol. Genet. 16 2007 2600 2615
167. K.B. Kegel, E. Sapp, J. Yoder, B. Cuiffo, L. Sobin, Y.J. Kim, Z.H. Qin, M.R. Hayden, N. Aronin, D.L. Scott, G. Isenberg, W.H. Goldmann, and M. DiFiglia Huntingtin associates with acidic phospholipids at the plasma membrane J. Biol. Chem. 280 2005 36464 36473
168. A.K. Thakur, M. Jayaraman, R. Mishra, M. Thakur, V.M. Chellgren, I.J. Byeon, D.H. Anjum, R. Kodali, T.P. Creamer, J.F. Conway, A.M. Gronenborn, and R. Wetzel Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism Nat. Struct. Mol. Biol. 16 2009 380 389
169. V.V. Lakhani, F. Ding, and N.V. Dokholyan Polyglutamine induced misfolding of huntingtin exon1 is modulated by the flanking sequences PLoS Comput. Biol. 6 2010 e1000772
170. N.S. Caron, C.R. Desmond, J. Xia, and R. Truant Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin Proc. Natl. Acad. Sci. U. S. A. 110 2013 14610 14615
171. T. Maiuri, T. Woloshansky, J. Xia, and R. Truant The huntingtin N17 domain is a multifunctional CRM1 and Ran-dependent nuclear and cilial export signal Hum. Mol. Genet. 22 2013 1383 1394
172. R.S. Atwal, C.R. Desmond, N. Caron, T. Maiuri, J. Xia, S. Sipione, and R. Truant Kinase inhibitors modulate huntingtin cell localization and toxicity Nat. Chem. Biol. 7 2011 453 460
173. R. Wetzel Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence J. Mol. Biol. 421 2012 466 490
174. S. Tam, C. Spiess, W. Auyeung, L. Joachimiak, B. Chen, M.A. Poirier, and J. Frydman The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation Nat. Struct. Mol. Biol. 16 2009 1279 1285
175. D.W. Colby, Y. Chu, J.P. Cassady, M. Duennwald, H. Zazulak, J.M. Webster, A. Messer, S. Lindquist, V.M. Ingram, and K.D. Wittrup Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody Proc. Natl. Acad. Sci. U. S. A. 101 2004 17616 17621
176. A.L. Southwell, J. Ko, and P.H. Patterson Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease J. Neurosci. 29 2009 13589 13602
177. A. Snyder-Keller, J.A. McLear, T. Hathorn, and A. Messer Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice J. Neuropathol. Exp. Neurol. 69 2010 1078 1085
178. D.C. Butler, and A. Messer Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments PLoS ONE 6 2011 e29199
179. O. Onodera, A.D. Roses, S. Tsuji, J.M. Vance, W.J. Strittmatter, and J.R. Burke Toxicity of expanded polyglutamine-domain proteins in Escherichia coli FEBS Lett. 399 1996 135 139
180. Y. Trottier, Y. Lutz, G. Stevanin, G. Imbert, D. Devys, G. Cancel, F. Saudou, C. Weber, G. David, and L. Tora Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias Nature 378 1995 403 406
181. V.C. Wheeler, J.K. White, C.A. Gutekunst, V. Vrbanac, M. Weaver, X.J. Li, S.H. Li, H. Yi, J.P. Vonsattel, J.F. Gusella, S. Hersch, W. Auerbach, A.L. Joyner, and M.E. MacDonald Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice Hum. Mol. Genet. 9 2000 503 513
182. P. Li, K.E. Huey-Tubman, T. Gao, X. Li, A.P. West Jr., M.J. Bennett, and P.J. Bjorkman The structure of a polyQ-anti-polyQ complex reveals binding according to a linear lattice model Nat. Struct. Mol. Biol. 14 2007 381 387
183. P.W. Faber, G.T. Barnes, J. Srinidhi, J. Chen, J.F. Gusella, and M.E. MacDonald Huntingtin interacts with a family of WW domain proteins Hum. Mol. Genet. 7 1998 1463 1474
184. J.S. Steffan, A. Kazantsev, O. Spasic-Boskovic, M. Greenwald, Y.Z. Zhu, H. Gohler, E.E. Wanker, G.P. Bates, D.E. Housman, and L.M. Thompson The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription Proc. Natl. Acad. Sci. U. S. A. 97 2000 6763 6768
185. G. Darnell, J.P. Orgel, R. Pahl, and S.C. Meredith Flanking polyproline sequences inhibit beta-sheet structure in polyglutamine segments by inducing PPII-like helix structure J. Mol. Biol. 374 2007 688 704
186. M.M. Hoehn, and M.D. Yahr Parkinsonism: onset, progression, and mortality. 1967 Neurology 57 2001 S11 S26
187. D.R. Williams, and I. Litvan Parkinsonian syndromes Continuum (Minneap. Minn.) 19 2013 1189 1212
188. M.R. Cookson, G. Xiromerisiou, and A. Singleton How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the disease Curr. Opin. Neurol. 18 2005 706 711
189. A.B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, J. Kachergus, M. Hulihan, T. Peuralinna, A. Dutra, R. Nussbaum, S. Lincoln, A. Crawley, M. Hanson, D. Maraganore, C. Adler, M.R. Cookson, M. Muenter, M. Baptista, D. Miller, J. Blancato, J. Hardy, and K. Gwinn-Hardy Alpha-synuclein locus triplication causes Parkinson's disease Science 302 2003 841
190. I.F. Mata, M. Shi, P. Agarwal, K.A. Chung, K.L. Edwards, S.A. Factor, D.R. Galasko, C. Ginghina, A. Griffith, D.S. Higgins, D.M. Kay, H. Kim, J.B. Leverenz, J.F. Quinn, J.W. Roberts, A. Samii, K.W. Snapinn, D.W. Tsuang, D. Yearout, J. Zhang, H. Payami, and C.P. Zabetian SNCA variant associated with Parkinson disease and plasma alpha-synuclein level Arch. Neurol. 67 2010 1350 1356
191. M. Bucciantini, E. Giannoni, F. Chiti, F. Baroni, L. Formigli, J. Zurdo, N. Taddei, G. Ramponi, C.M. Dobson, and M. Stefani Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases Nature 416 2002 507 511
192. A. Olofsson, J. Ostman, and E. Lundgren Amyloid: morphology and toxicity Clin. Chem. Lab. Med. 40 2002 1266 1270
193. S.J. Lee, P. Desplats, H.J. Lee, B. Spencer, and E. Masliah Cell-to-cell transmission of alpha-synuclein aggregates Methods Mol. Biol. 849 2012 347 359
194. B. Obermeier, R. Daneman, and R.M. Ransohoff Development, maintenance and disruption of the blood-brain barrier Nat. Med. 19 2013 1584 1596
195. J.A. Couch, Y.J. Yu, Y. Zhang, J.M. Tarrant, R.N. Fuji, W.J. Meilandt, H. Solanoy, R.K. Tong, K. Hoyte, W. Luk, Y. Lu, K. Gadkar, S. Prabhu, B.A. Ordonia, Q. Nguyen, Y. Lin, Z. Lin, M. Balazs, K. Scearce-Levie, J.A. Ernst, M.S. Dennis, and R.J. Watts Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier Sci. Transl. Med. 5 2013 183ra157 (181-112)
196. N. Bien-Ly, Y.J. Yu, D. Bumbaca, J. Elstrott, C.A. Boswell, Y. Zhang, W. Luk, Y. Lu, M.S. Dennis, R.M. Weimer, I. Chung, and R.J. Watts Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants J. Exp. Med. 211 2014 233 244
197. M.S. Dennis, and R.J. Watts Transferrin antibodies into the brain Neuropsychopharmacology 37 2012 302 303
198. Y.J. Yu, Y. Zhang, M. Kenrick, K. Hoyte, W. Luk, Y. Lu, J. Atwal, J.M. Elliott, S. Prabhu, R.J. Watts, and M.S. Dennis Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target Sci. Transl. Med. 3 2011 84ra44
199. M. Colozza, E. Minenza, S. Gori, D. Fenocchio, C. Paolucci, C. Aristei, and P. Floridi Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab Cancer Chemother. Pharmacol. 63 2009 1157 1159
200. R.H. Bobo, D.W. Laske, A. Akbasak, P.F. Morrison, R.L. Dedrick, and E.H. Oldfield Convection-enhanced delivery of macromolecules in the brain Proc. Natl. Acad. Sci. U. S. A. 91 1994 2076 2080
201. R.T. Frank, K.S. Aboody, and J. Najbauer Strategies for enhancing antibody delivery to the brain Biochim. Biophys. Acta 1816 2011 191 198
202. M.A. Passini, D.J. Watson, C.H. Vite, D.J. Landsburg, A.L. Feigenbaum, and J.H. Wolfe Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice J. Virol. 77 2003 7034 7040
203. C.G. Bien, A. Vincent, M.H. Barnett, A.J. Becker, I. Blumcke, F. Graus, K.A. Jellinger, D.E. Reuss, T. Ribalta, J. Schlegel, I. Sutton, H. Lassmann, and J. Bauer Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis Brain 135 2012 1622 1638
204. J.E. Greenlee, S.A. Clawson, K.E. Hill, B.L. Wood, I. Tsunoda, and N.G. Carlson Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures J. Neuropathol. Exp. Neurol. 69 2010 997 1007
205. K.L. Sudol, M.A. Mastrangelo, W.C. Narrow, M.E. Frazer, Y.R. Levites, T.E. Golde, H.J. Federoff, and W.J. Bowers Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer's disease Mol. Ther. 17 2009 2031 2040
206. D. Schenk, M. Hagen, and P. Seubert Current progress in beta-amyloid immunotherapy Curr. Opin. Immunol. 16 2004 599 606
207. S. Salloway, R. Sperling, S. Gilman, N.C. Fox, K. Blennow, M. Raskind, M. Sabbagh, L.S. Honig, R. Doody, C.H. van Dyck, R. Mulnard, J. Barakos, K.M. Gregg, E. Liu, I. Lieberburg, D. Schenk, R. Black, and M. Grundman A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 73 2009 2061 2070
208. B. Winblad, A. Graf, M.E. Riviere, N. Andreasen, and J.M. Ryan Active immunotherapy options for Alzheimer's disease Alzheimers Res. Ther. 6 2014 7
209. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L. Mutter, F. Soriano, G. Shopp, N. Vasquez, C. Vandevert, S. Walker, M. Wogulis, T. Yednock, D. Games, and P. Seubert Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400 1999 173 177
210. F. Bard, R. Barbour, C. Cannon, R. Carretto, M. Fox, D. Games, T. Guido, K. Hoenow, K. Hu, K. Johnson-Wood, K. Khan, D. Kholodenko, C. Lee, M. Lee, R. Motter, M. Nguyen, A. Reed, D. Schenk, P. Tang, N. Vasquez, P. Seubert, and T. Yednock Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology Proc. Natl. Acad. Sci. U. S. A. 100 2003 2023 2028
211. E. Masliah, E. Rockenstein, M. Mante, L. Crews, B. Spencer, A. Adame, C. Patrick, M. Trejo, K. Ubhi, T.T. Rohn, S. Mueller-Steiner, P. Seubert, R. Barbour, L. McConlogue, M. Buttini, D. Games, and D. Schenk Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease PLoS ONE 6 2011 e19338
212. C.A. Lemere Immunotherapy for Alzheimer's disease: hoops and hurdles Mol. Neurodegener. 8 2013 36
213. B. Solomon Immunological approaches as therapy for Alzheimer's disease Expert. Opin. Biol. Ther. 2 2002 907 917
214. E. Valera, and E. Masliah Immunotherapy for neurodegenerative diseases: focus on alpha-synucleinopathies Pharmacol. Ther. 138 2013 311 322
215. S. Gilman, M. Koller, R.S. Black, L. Jenkins, S.G. Griffith, N.C. Fox, L. Eisner, L. Kirby, M.B. Rovira, F. Forette, and J.M. Orgogozo Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial Neurology 64 2005 1553 1562
216. J.M. Orgogozo, S. Gilman, J.F. Dartigues, B. Laurent, M. Puel, L.C. Kirby, P. Jouanny, B. Dubois, L. Eisner, S. Flitman, B.F. Michel, M. Boada, A. Frank, and C. Hock Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization Neurology 61 2003 46 54
217. G.A. Kerchner, and A.L. Boxer Bapineuzumab Expert. Opin. Biol. Ther. 10 2010 1121 1130
218. H. Samadi, and D. Sultzer Solanezumab for Alzheimer's disease Expert. Opin. Biol. Ther. 11 2011 787 798
219. R.S. Doody, R.G. Thomas, M. Farlow, T. Iwatsubo, B. Vellas, S. Joffe, K. Kieburtz, R. Raman, X. Sun, P.S. Aisen, E. Siemers, H. Liu-Seifert, and R. Mohs Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease N. Engl. J. Med. 370 2014 311 321
220. S. Salloway, R. Sperling, N.C. Fox, K. Blennow, W. Klunk, M. Raskind, M. Sabbagh, L.S. Honig, A.P. Porsteinsson, S. Ferris, M. Reichert, N. Ketter, B. Nejadnik, V. Guenzler, M. Miloslavsky, D. Wang, Y. Lu, J. Lull, I.C. Tudor, E. Liu, M. Grundman, E. Yuen, R. Black, and H.R. Brashear Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease N. Engl. J. Med. 370 2014 322 333